Schizophrenia: Genetics, prevention and rehabilitation: Review article

Acta Neuropsychiatrica

Volumn 21, Issue 3, 2009, Pages 109-120

  Olgiati, Paolo ^a   Mandelli, Laura ^a   Lorenzi, Cristina ^b   Marino, Elena ^b   Adele, Pirovano ^b   Ferrari, Barbara ^a   De Ronchi, Diana ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Endophenotypes; Gene; Prevention; Rehabilitation; Review; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DYSBINDIN; METABOTROPIC RECEPTOR 3; NEU DIFFERENTIATION FACTOR; PROTEIN AKT 1; PROTEIN DISC 1; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

COGNITION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; LIFE STRESS; MEDLINE; PERINATAL PERIOD; PHENOTYPE; PRENATAL PERIOD; PREVALENCE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 68049131598     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2009.00360.x     Document Type: Review

References (175)

1. Tsuang MT, Stone WS, Faraone SV. Genes, environment and schizophrenia. Br J Psychiatry 2001 40 (Suppl s18 s24.
2. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003 60 : 1187 1192.
3. Cardno AG, Marshall EJ, Coid B et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999 56 : 162 168.
4. Portin P, Alanen YO. A critical review of genetic studies of schizophrenia. I. Epidemiological and brain studies. Acta Psychiatr Scand 1997 95 : 1 5. (Pubitemid 27064720)
5. Levinson DF, Levinson MD, Segurado R, Lewis CM. Genome scan meta-analysis of schizophrenia and bipolar disorder, part I: Methods and power analysis. Am J Hum Genet 2003 73 : 17 33. (Pubitemid 36793777)
6. Lewis CM, Levinson DF, Wise LH et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003 73 : 17 33.
7. Segurado R, Detera-Wadleigh SD, Levinson DF et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 2003 73 : 34 48.
8. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 2003 33 (Suppl 228 237.
9. Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003 27 : 269 306.
10. Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar VL, Thelma BK. Molecular genetics of schizophrenia: past, present and future. J Biosci 2002 27 (Suppl 1 35 52.
11. Karoutzou G, Emrich H, Dietrich D. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 2008 13 : 245 260.
12. Nurnberger JI Jr., Blehar MC, Kaufmann CA et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994 51 : 849 859 discussion 863-864.
13. Park N, Juo S, Cheng R et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry 2004 9 : 1091 1099.
14. Kendler KS. "A gene for...": the nature of gene action in psychiatric disorders. Am J Psychiatry 2005 162 : 1243 1252.
15. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003 160 : 636 645.
16. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006 67 (Suppl 9 3 8 discussion 36-42.
17. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007 11 : 1189 1206.
18. Boog G. [Obstetrical complications and further schizophrenia of the infant: a new medicolegal threat to the obstetrician?]. J Gynecol Obstet Biol Reprod (Paris) 2003 32 : 720 727.
19. Pearce BD. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 2001 6 : 634 646.
20. Cullberg J. Stressful life events preceding the first onset of psychosis. An explorative study. Nord J Psychiatry 2003 57 : 209 214.
21. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007 370 : 319 328.
22. McDonald C, Murray RM. Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev 2000 31 : 130 137.
23. Tienari P, Wynne LC, Moring J et al. The Finnish adoptive family study of schizophrenia. Implications for family research. Br J Psychiatry 1994 Suppl 20 26.
24. Tienari P, Wynne LC, Sorri A et al. Genotype-environment interaction in schizophrenia-spectrum disorder. Long-term follow-up study of Finnish adoptees. Br J Psychiatry 2004 184 : 216 222.
25. Fioravanti M, Carlone O, Vitale B, Cinti M, Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev 2005 15 : 73 95.
26. Sitskoorn M, Aleman A, Ebisch S, Appels M, Kahn R. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004 71 : 285 295.
27. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res 1998 33 : 157 167.
28. Shajahan PM, O'Carroll RE, Glabus MF, Ebmeier KP, Blackwood DH. Correlation of auditory 'oddball' P300 with verbal memory deficits in schizophrenia. Psychol Med 1997 27 : 579 586.
29. Souza VB, Muir WJ, Walker MT et al. Auditory P300 event-related potentials and neuropsychological performance in schizophrenia and bipolar affective disorder. Biol Psychiatry 1995 37 : 300 310.
30. Patterson JV, Hetrick WP, Boutros NN et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008 158 : 226 247.
31. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007 33 : 69 94.
32. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000 157 : 767 771.
33. Umbricht D, Javitt D, Novak G et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998 44 : 716 725.
34. Grossman MH, Littrell J, Weinstein R, Punnett HH, Emanuel BS, Budarf M. The gene for human catechol-O-methyltransferase (COMT) maps to 22pter-22q11.1. Cytogenet Cell Genet 1991 58 : 2048.
35. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996 6 : 243 250.
36. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003 160 : 469 476.
37. Gosso MF, de Geus EJ, Polderman TJ, Boomsma DI, Heutink P, Posthuma D. Catechol O-methyl transferase and dopamine D2 receptor gene polymorphisms: evidence of positive heterosis and gene-gene interaction on working memory functioning. Eur J Hum Genet 2008 16 : 1075 1082.
38. Opgen-Rhein C, Neuhaus AH, Urbanek C, Hahn E, Sander T, Dettling M. Executive attention in schizophrenic males and the impact of COMT val108/158met genotype on performance on the attention network test. Schizophr Bull 2008 34 : 1231 1239.
39. Alfimova MV, Golimbet VE, Gritsenko IK et al. Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population. Neurosci Behav Physiol 2007 37 : 643 650.
40. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007 90 : 86 96.
41. Rybakowski JK, Borkowska A, Czerski PM et al. Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET). Psychiatry Res 2006 143 : 13 19.
42. Minzenberg MJ, Xu K, Mitropoulou V et al. Catechol-O-methyltransferase Val158Met genotype variation is associated with prefrontal-dependent task performance in schizotypal personality disorder patients and comparison groups. Psychiatr Genet 2006 16 : 117 124.
43. Stefanis NC, van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Stefanis CN. Effect of COMT Val158Met polymorphism on the continuous performance test, identical Pairs version: tuning rather than improving performance. Am J Psychiatry 2005 162 : 1752 1754.
44. Galderisi S, Maj M, Kirkpatrick B et al. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 2005 52 : 83 89.
45. Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 2004 161 : 359 361.
46. Goldberg TE, Egan MF, Gscheidle T et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003 60 : 889 896.
47. Egan MF, Goldberg TE, Kolachana BS et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001 98 : 6917 6922.
48. Lu BY, Martin KE, Edgar JC et al. Effect of catechol O-methyltransferase val(158)met polymorphism on the p50 gating endophenotype in schizophrenia. Biol Psychiatry 2007 62 : 822 825.
49. Ma X, Sun J, Yao J et al. A quantitative association study between schizotypal traits and COMT, PRODH and BDNF genes in a healthy Chinese population. Psychiatry Res 2007 153 : 7 15.
50. Schurhoff F, Szoke A, Chevalier F et al. Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. Am J Med Genet B Neuropsychiatr Genet 2007 144 : 64 68.
51. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003 284 : 14 30.
52. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007 190 : 1 65.
53. Bjarnadottir M, Misner DL, Haverfield-Gross S et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J Neurosci 2007 27 : 4519 4529.
54. Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004 7 : 575 580.
55. O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 2007 31 : 60 78.
56. Karl T, Duffy L, Scimone A, Harvey RP, Schofield PR. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 2007 6 : 677 687.
57. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002 7 : 405 411.
58. Li D, Collier D, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006 15 : 1992 2002.
59. Stefanis NC, Trikalinos TA, Avramopoulos D et al. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol Psychiatry 2007 62 : 784 792.
60. Lang UE, Jockers-Scherubl MC, Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J Neural Transm 2004 111 : 387 411.
61. Takahashi M, Shirakawa O, Toyooka K et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000 5 : 293 300.
62. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003 8 : 592 610.
63. Ringstedt T, Linnarsson S, Wagner J et al. BDNF regulates reelin expression and Cajal-Retzius cell development in the cerebral cortex. Neuron 1998 21 : 305 315.
64. Alcantara S, Pozas E, Ibanez CF, Soriano E. BDNF-modulated spatial organization of Cajal-Retzius and GABAergic neurons in the marginal zone plays a role in the development of cortical organization. Cereb Cortex 2006 16 : 487 499.
65. Rice DS, Curran T. Role of the reelin signaling pathway in central nervous system development. Annu Rev Neurosci 2001 24 : 1005 1039.
66. Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000 60 : 783 794.
67. Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001 14 : 135 144.
68. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005 382 : 27 32.
69. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007 41 : 31 35.
70. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007 61 : 911 922.
71. Zintzaras E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr Genet 2007 17 : 69 75.
72. Kanazawa T, Glatt SJ, Kia-Keating B, Yoneda H, Tsuang MT. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007 17 : 165 170.
73. Rybakowski JK, Borkowska A, Skibinska M et al. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci 2006 60 : 70 76.
74. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006 63 : 731 40.
75. Millar JK, Wilson-Annan JC, Anderson S et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000 9 : 1415 1423.
76. Ishizuka K, Paek M, Kamiya A, Sawa A. A review of Disrupted-In- Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol Psychiatry 2006 59 : 1189 1197.
77. Brandon NJ, Handford EJ, Schurov I et al. Disrupted in schizophrenia 1 and nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Mol Cell Neurosci 2004 25 : 42 55.
78. Kamiya A, Tomoda T, Chang J et al. DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Hum Mol Genet 2006 15 : 3313 3323.
79. Duan X, Chang JH, Ge S et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007 130 : 1146 1158. (Pubitemid 47422304)
80. Roberts RC. Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophr Bull 2007 33 : 11 15.
81. Morris J, Kandpal G, Ma L, Austin C. DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet 2003 12 : 1591 1608.
82. Millar JK, Pickard BS, Mackie S et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005 310 : 1187 1191.
83. Liu YL, Fann CS, Liu CM et al. A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: association with impairment of sustained attention. Biol Psychiatry 2006 60 : 554 562.
84. Hennah W, Tuulio-Henriksson A, Paunio T et al. A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol Psychiatry 2005 10 : 1097 1103.
85. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001 276 : 24232 24241.
86. Numakawa T, Yagasaki Y, Ishimoto T et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004 13 : 2699 2708.
87. Talbot K, Eidem WL, Tinsley CL et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004 113 : 1353 1363.
88. Weickert CS, Straub RE, McClintock BW et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004 61 : 544 555.
89. Bray NJ, Preece A, Williams NM et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005 14 : 1947 1954.
90. Guo AY, Sun J, Riley BP, Thiselton DL, Kendler KS, Zhao Z. The dystrobrevin-binding protein 1 gene: features and networks. Mol Psychiatry 2009 14 : 18 29.
91. Donohoe G, Morris DW, De Sanctis P et al. Early visual processing deficits in dysbindin-associated schizophrenia. Biol Psychiatry 2008 63 : 484 489.
92. Donohoe G, Morris DW, Clarke S et al. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007 45 : 454 458. (Pubitemid 44828767)
93. Burdick KE, Lencz T, Funke B et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet 2006 15 : 1563 1568.
94. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996 3 : 241 53.
95. Clark M, Johnson BG, Wright RA, Monn JA, Schoepp DD. Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacol Biochem Behav 2002 73 : 339 346.
96. Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007 13 : 1102 1107.
97. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008 22 : 308 322.
98. Egan MF, Straub RE, Goldberg TE et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 2004 101 : 12604 12609.
99. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992 32 : 607 616.
100. Adler LE, Olincy A, Cawthra E et al. Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism. Neuropsychopharmacology 2001 24 : 671 679.
101. Freedman R, Olincy A, Ross RG et al. The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 2003 5 : 155 161.
102. Houy E, Raux G, Thibaut F et al. The promoter -194 C polymorphism of the nicotinic alpha 7 receptor gene has a protective effect against the P50 sensory gating deficit. Mol Psychiatry 2004 9 : 320 322.
103. Martin LF, Leonard S, Hall MH, Tregellas JR, Freedman R, Olincy A. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 2007 144 : 611 614.
104. McGuffin P, Asherson P, Owen M, Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994 164 : 593 599.
105. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull 2006 32 : 3 8.
106. Preti A, Cardascia L, Zen T, Marchetti M, Favaretto G, Miotto P. Risk for obstetric complications and schizophrenia. Psychiatry Res 2000 96 : 127 139.
107. Dalman C, Thomas HV, David AS, Gentz J, Lewis G, Allebeck P. Signs of asphyxia at birth and risk of schizophrenia. Population-based case-control study. Br J Psychiatry 2001 179 : 403 408.
108. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007 97 : 51 59.
109. Cannon TD, van Erp TG, Rosso IM et al. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry 2002 59 : 35 41.
110. Schmidt-Kastner R, van Os J, Steinbusch HWM, Schmitz C. Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr Res 2006 84 : 253 271.
111. Nadri C, Belmaker RH, Agam G. Oxygen restriction of neonate rats elevates neuregulin-1alpha isoform levels: possible relationship to schizophrenia. Neurochem Int 2007 51 : 447 450.
112. Nicodemus KK, Marenco S, Batten AJ et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry 2008 13 : 873 877.
113. Castle D, Gill M. Maternal viral infection and schizophrenia. Br J Psychiatry 1992 161 : 273 274.
114. Limosin F, Rouillon F, Payan C, Cohen JM, Strub N. Prenatal exposure to influenza as a risk factor for adult schizophrenia. Acta Psychiatr Scand 2003 107 : 331 335.
115. Fatemi SH, Cuadra AE, El-Fakahany EE, Sidwell RW, Thuras P. Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport 2000 11 : 1493 1496.
116. Fatemi SH, Earle J, Kanodia R et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell Mol Neurobiol 2002 22 : 25 33.
117. Fatemi SH, Emamian ES, Sidwell RW et al. Human influenza viral infection in utero alters glial fibrillary acidic protein immunoreactivity in the developing brains of neonatal mice. Mol Psychiatry 2002 7 : 633 640.
118. Torrey EF, Leweke MF, Schwarz MJ et al. Cytomegalovirus and schizophrenia. CNS Drugs 2006 20 : 879 885.
119. Leweke FM, Gerth CW, Koethe D et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004 254 : 4 8.
120. Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Yolken RH. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003 160 : 2234 2236.
121. Beraki S, Aronsson F, Karlsson H, Ogren SO, Kristensson K. Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Mol Psychiatry 2005 10 : 299 308.
122. Kim JJ, Shirts BH, Dayal M et al. Are exposure to cytomegalovirus and genetic variation on chromosome 6p joint risk factors for schizophrenia? Ann Med 2007 39 : 145 153.
123. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998 24 : 443 455.
124. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 1998 28 : 1411 1419.
125. Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000 26 : 343 353.
126. Buhler B, Hambrecht M, Loffler W, an der Heiden W, Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002 54 : 243 251.
127. Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005 330 : 11.
128. McGuire P, Jones P, Harvey I, Williams M, McGuffin P, Murray R. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995 15 : 277 281.
129. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005 57 : 1117 1127.
130. Henquet C, Rosa A, Krabbendam L et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006 31 : 2748 2757.
131. Zammit S, Spurlock G, Williams H et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007 191 : 402 407.
132. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology 2007 192 : 325 336.
133. Kishimoto M, Ujike H, Motohashi Y et al. The Dysbindin Gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry 2008 63 : 191 196.
134. Ventura J, Nuechterlein KH, Subotnik KL, Hardesty JP, Mintz J. Life events can trigger depressive exacerbation in the early course of schizophrenia. J Abnorm Psychol 2000 109 : 139 144.
135. Myin-Germeys I, Peeters F, Havermans R et al. Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr Scand 2003 107 : 124 131. (Pubitemid 36164480)
136. Myin-Germeys I, van Os J. Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clin Psychol Rev 2007 27 : 409 424.
137. Stefanis NC, Henquet C, Avramopoulos D et al. COMT Val158Met moderation of stress-induced psychosis. Psychol Med 2007 37 : 1651 1656.
138. van Winkel R, Henquet C, Rosa A et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet 2008 147B : 10 17.
139. Kendler KS, Eaves LJ. Models for the joint effect of genotype and environment on liability to psychiatric illness. Am J Psychiatry 1986 143 : 279 289.
140. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007 10 : 537 545.
141. Dwork AJ, Mancevski B, Rosoklija G. White matter and cognitive function in schizophrenia. Int J Neuropsychopharmacol 2007 10 : 513 536.
142. Schlaepfer TE, Lancaster E, Heidbreder R et al. Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol 2006 9 : 147 153.
143. Kumra S. Schizophrenia and cannabis use. Minn Med 2007 90 : 36 38.
144. Doane JA. Family interaction and communication deviance in disturbed and normal families: a review of research. Fam Process 1978 17 : 357 376.
145. Miklowitz DJ, Stackman D. Communication deviance in families of schizophrenic and other psychiatric patients: current state of the construct. Prog Exp Pers Psychopathol Res 1992 15 : 1 46.
146. Velligan DI, Mahurin RK, Eckert SL, Hazleton BC, Miller A. Relationship between specific types of communication deviance and attentional performance in patients with schizophrenia. Psychiatry Res 1997 70 : 9 20.
147. Wahlberg KE, Wynne LC, Oja H et al. Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Am J Psychiatry 1997 154 : 355 362.
148. Wahlberg KE, Wynne LC, Hakko H et al. Interaction of genetic risk and adoptive parent communication deviance: longitudinal prediction of adoptee psychiatric disorders. Psychol Med 2004 34 : 1531 1541.
149. Subotnik KL, Goldstein MJ, Nuechterlein KH, Woo SM, Mintz J. Are communication deviance and expressed emotion related to family history of psychiatric disorders in schizophrenia? Schizophr Bull 2002 28 : 719 729.
150. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry 2000 34 (Suppl S164 S169.
151. McGorry PD, Yung AR, Phillips LJ. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003 29 : 771 790.
152. Yung AR, Phillips LJ, Yuen HP et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 2003 60 : 21 32.
153. Amminger GP, Leicester S, Yung AR et al. Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res 2006 84 : 67 76.
154. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull 2007 33 : 661 664.
155. Rentzsch J, Penzhorn A, Kernbichler K et al. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp Neurol 2007 205 : 241 249.
156. Patrick G, Struve FA. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalogr 2000 31 : 88 93.
157. Patrick G, Straumanis JJ, Struve FA, Fitz-Gerald MJ, Leavitt J, Manno JE. Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biol Psychiatry 1999 45 : 1307 1312.
158. Oranje B, Van Oel CJ, Gispen-De Wied CC, Verbaten MN, Kahn RS. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 2002 22 : 359 365.
159. Donohoe G, Corvin A, Robertson IH. Evidence that specific executive functions predict symptom variance among schizophrenia patients with a predominantly negative symptom profile. Cogn Neuropsychiatry 2006 11 : 13 32.
160. Cameron AM, Oram J, Geffen GM, Kavanagh DJ, McGrath JJ, Geffen LB. Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res 2002 110 : 49 61.
161. Daban C, Amado I, Bayle F et al. Disorganization syndrome is correlated to working memory deficits in unmedicated schizophrenic patients with recent onset schizophrenia. Schizophr Res 2003 61 : 323 324.
162. Hofer A, Baumgartner S, Bodner T et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry 2005 20 : 395 402.
163. Prouteau A, Verdoux H, Briand C et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res 2005 77 : 343 353.
164. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005 162 : 495 506.
165. Stirling J, White C, Lewis S et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res 2003 65 : 75 86.
166. Martinez-Aran A, Penades R, Vieta E et al. Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychother Psychosom 2002 71 : 39 46.
167. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004 72 : 41 51.
168. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther 2005 27 (Suppl A S25 S37.
169. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003 28 (Suppl 1 27 38.
170. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl) 2002 162 : 11 17.
171. Woodward N, Purdon S, Meltzer H, Zald D. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005 8 : 457 472.
172. Green M. Cognitive remediation in schizophrenia: is it time yet? Am J Psychiatry 1993 150 : 178 187.
173. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007 164 : 1791 1802.
174. Wykes T, van der Gaag M. Is it time to develop a new cognitive therapy for psychosis-cognitive remediation therapy (CRT)? Clin Psychol Rev 2001 21 : 1227 1256.
175. Bosia M, Bechi M, Marino E et al. Influence of catechol-O- methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett 2007 417 : 271 274.